SurgePays (SURG) Competitors $2.73 -0.04 (-1.44%) Closing price 10/16/2025 04:00 PM EasternExtended Trading$2.82 +0.09 (+3.26%) As of 07:00 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipShort InterestTrendsBuy This Stock SURG vs. TLSI, CV, ELMD, KRMD, INFU, STIM, SKIN, PROF, SGHT, and AVRShould you be buying SurgePays stock or one of its competitors? The main competitors of SurgePays include TriSalus Life Sciences (TLSI), CapsoVision (CV), Electromed (ELMD), KORU Medical Systems (KRMD), InfuSystem (INFU), Neuronetics (STIM), Beauty Health (SKIN), Profound Medical (PROF), Sight Sciences (SGHT), and Anteris Technologies Global (AVR). These companies are all part of the "medical equipment" industry. SurgePays vs. Its Competitors TriSalus Life Sciences CapsoVision Electromed KORU Medical Systems InfuSystem Neuronetics Beauty Health Profound Medical Sight Sciences Anteris Technologies Global SurgePays (NASDAQ:SURG) and TriSalus Life Sciences (NASDAQ:TLSI) are both small-cap medical equipment companies, but which is the better business? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, profitability, media sentiment, dividends, valuation and earnings. Which has better earnings & valuation, SURG or TLSI? TriSalus Life Sciences has lower revenue, but higher earnings than SurgePays. TriSalus Life Sciences is trading at a lower price-to-earnings ratio than SurgePays, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSurgePays$60.88M0.92-$45.73M-$2.49-1.10TriSalus Life Sciences$29.43M8.05-$30.05M-$1.18-4.03 Do institutionals & insiders believe in SURG or TLSI? 6.9% of SurgePays shares are owned by institutional investors. Comparatively, 2.6% of TriSalus Life Sciences shares are owned by institutional investors. 30.5% of SurgePays shares are owned by company insiders. Comparatively, 27.5% of TriSalus Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term. Does the media favor SURG or TLSI? In the previous week, SurgePays had 1 more articles in the media than TriSalus Life Sciences. MarketBeat recorded 4 mentions for SurgePays and 3 mentions for TriSalus Life Sciences. TriSalus Life Sciences' average media sentiment score of 0.57 beat SurgePays' score of 0.46 indicating that TriSalus Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment SurgePays 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral TriSalus Life Sciences 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is SURG or TLSI more profitable? TriSalus Life Sciences has a net margin of -86.61% compared to SurgePays' net margin of -133.85%. TriSalus Life Sciences' return on equity of 0.00% beat SurgePays' return on equity.Company Net Margins Return on Equity Return on Assets SurgePays-133.85% -333.87% -195.36% TriSalus Life Sciences -86.61%N/A -116.50% Do analysts recommend SURG or TLSI? SurgePays presently has a consensus target price of $9.50, indicating a potential upside of 247.99%. TriSalus Life Sciences has a consensus target price of $10.90, indicating a potential upside of 129.47%. Given SurgePays' higher probable upside, research analysts plainly believe SurgePays is more favorable than TriSalus Life Sciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score SurgePays 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00TriSalus Life Sciences 1 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.00 Which has more risk and volatility, SURG or TLSI? SurgePays has a beta of 0.43, meaning that its share price is 57% less volatile than the S&P 500. Comparatively, TriSalus Life Sciences has a beta of 0.47, meaning that its share price is 53% less volatile than the S&P 500. SummaryTriSalus Life Sciences beats SurgePays on 11 of the 17 factors compared between the two stocks. Get SurgePays News Delivered to You Automatically Sign up to receive the latest news and ratings for SURG and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SURG and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SURG vs. The Competition Export to ExcelMetricSurgePaysINTERNET SOFTWARE IndustryComputer SectorNASDAQ ExchangeMarket Cap$56.60M$19.53B$32.76B$10.55BDividend YieldN/A3.63%3.20%4.78%P/E Ratio-1.1071.70488.7127.19Price / Sales0.92110.711,483.02132.96Price / CashN/A82.5938.1062.13Price / Book3.599.247.516.65Net Income-$45.73M$356.34M$820.59M$276.79M7 Day Performance3.02%0.04%1.25%1.75%1 Month Performance-7.46%-0.86%3.44%5.15%1 Year Performance47.57%75.41%23,917.24%36.96% SurgePays Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SURGSurgePays2.5748 of 5 stars$2.73-1.4%$9.50+248.0%+44.4%$56.60M$60.88M-1.1040News CoverageGap UpHigh Trading VolumeTLSITriSalus Life Sciences2.2955 of 5 stars$4.59+6.3%$10.90+137.5%+5.8%$215.43M$29.43M-3.89106Short Interest ↑CVCapsoVisionN/A$4.67+4.7%$5.50+17.8%N/A$208.61MN/A0.0090Short Interest ↑ELMDElectromed3.3886 of 5 stars$24.55+1.9%$36.25+47.7%+5.4%$205.63M$64M32.73160KRMDKORU Medical Systems1.677 of 5 stars$4.07-5.1%$4.63+13.6%+51.1%$198.35M$33.65M-45.2280INFUInfuSystem4.0675 of 5 stars$9.22-0.1%$13.50+46.4%+31.6%$188.33M$139.89M153.69410Positive NewsShort Interest ↑STIMNeuronetics2.2517 of 5 stars$2.76-1.1%$7.00+153.6%+214.4%$184.49M$74.89M-2.44180SKINBeauty Health2.1314 of 5 stars$1.52+5.6%$2.81+85.0%-11.7%$182.63M$334.30M-5.431,030PROFProfound Medical1.6772 of 5 stars$5.98+1.9%$11.00+83.9%-26.9%$176.81M$10.68M-4.10150News CoverageSGHTSight Sciences3.5041 of 5 stars$3.26+1.9%$4.33+32.9%-42.7%$167.58M$79.87M-3.40210AVRAnteris Technologies Global1.8273 of 5 stars$4.45-3.5%$16.50+270.8%N/A$166.25M$2.70M0.00138News CoverageShort Interest ↑ Related Companies and Tools Related Companies TriSalus Life Sciences Competitors CapsoVision Competitors Electromed Competitors KORU Medical Systems Competitors InfuSystem Competitors Neuronetics Competitors Beauty Health Competitors Profound Medical Competitors Sight Sciences Competitors Anteris Technologies Global Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SURG) was last updated on 10/17/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | Sponsored$15 Fund: Turn Gold Boom into Real IncomeIf you've been watching gold's historic run and wondering if it's too late… I've got good news. Because the...Investors Alley | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding SurgePays, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share SurgePays With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
